Recognition of non-operating income
CanBas Co.,Ltd. (the Company)
The Company's deposits, foreign-currency-denominated accounts payable including clinical trial preparation costs, and foreign-currency deposits
The interest income relates to interest earned on the Company's deposits. The foreign exchange gains resulted from fluctuations in exchange rates applied to foreign-currency-denominated accounts payable, including clinical trial preparation costs, and foreign-currency deposits.
Interest income of ¥2,183 thousand (non-operating income) and foreign exchange gains of ¥9,184 thousand (non-operating income). Foreign exchange gains for the cumulative third-quarter period of the fiscal year ending June 2026 were ¥38,879 thousand (non-operating income).
The third-quarter accounting period of the fiscal year ending June 2026 (1 January 2026–31 March 2026). Foreign exchange gains of ¥38,879 thousand were recorded during the cumulative third-quarter period of the fiscal year ending June 2026 (1 July 2025–31 March 2026).
This matter has been reflected in the "Financial Results for the Third Quarter (Interim Period) of the Fiscal Year Ending June 2026 [Japanese GAAP] (Non-consolidated)," released today. Revision of the earnings forecast: Not disclosed.
This matter has been reflected in the financial results for the third quarter of the fiscal year ending June 2026, released today.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating income |
| Date of occurrence | 1 January 2026–31 March 2026 (during the third-quarter accounting period of the fiscal year ending June 2026; individual date of occurrence: Not disclosed) |
| Subject Entity | CanBas Co.,Ltd. (the Company) |
| Target Locations / Products | The Company's deposits, foreign-currency-denominated accounts payable including clinical trial preparation costs, and foreign-currency deposits |
| Cause | The interest income relates to interest earned on the Company's deposits. The foreign exchange gains resulted from fluctuations in exchange rates applied to foreign-currency-denominated accounts payable, including clinical trial preparation costs, and foreign-currency deposits. |
| Amount of Impact on Business Performance | Interest income of ¥2,183 thousand (non-operating income) and foreign exchange gains of ¥9,184 thousand (non-operating income). Foreign exchange gains for the cumulative third-quarter period of the fiscal year ending June 2026 were ¥38,879 thousand (non-operating income). |
| Accounting period in which recognized | The third-quarter accounting period of the fiscal year ending June 2026 (1 January 2026–31 March 2026). Foreign exchange gains of ¥38,879 thousand were recorded during the cumulative third-quarter period of the fiscal year ending June 2026 (1 July 2025–31 March 2026). |
| Impact on Earnings Forecast | This matter has been reflected in the "Financial Results for the Third Quarter (Interim Period) of the Fiscal Year Ending June 2026 [Japanese GAAP] (Non-consolidated)," released today. Revision of the earnings forecast: Not disclosed. |
| Outlook | This matter has been reflected in the financial results for the third quarter of the fiscal year ending June 2026, released today. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The interest income relates to interest earned on the Company's deposits. The foreign exchange gains resulted from fluctuations in exchange rates applied to foreign-currency-denominated accounts payable, including clinical trial preparation costs, and foreign-currency deposits.